Condition: Urinary Bladder Neoplasms · Non-Muscle Invasive Bladder Neoplasms · Carcinoma in Situ · Sponsor: Merck Sharp & Dohme LLC
Researchers are looking for new ways to treat people with high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder but has not spread to the bladder muscle or outside of the bladder. High-risk means NMIBC may have a high chance of getting worse or coming back after treatment. HR NMIBC can also include carcinoma in situ (CIS). CIS is bladder cancer that appears flat and is only in the inner layer (surface) of the bladder. CIS is not raised and is not growing toward the center of the bladder. The standard treatment for HR NMIBC is a procedure to remove the tumor called transurethral resection of the bladder tumor (TURBT) followed by Bacillus Calmette-Guerin (BCG). Standard treatment is something that is considered the first line of treatment for a condition. BCG is an immunotherapy, which is a treatment that helps the immune system fight cancer. However, BCG may not work to treat HR NMIBC in some people. Researchers want to learn if adding intismeran autogene, the study treatment, to standard treatment can help treat HR NMIBC. Intismeran autogene is designed to help a person's immune system attack their specific cancer. The goal of this study are to learn if people who receive V940 with BCG live longer and without the cancer growing, spreading, or coming back compared to people who receive BCG alone.
This description comes directly from the study's public registry record.
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
| Michael G Oefelein Clinical Trials ( Site 0138) | Bakersfield, California, United States | Recruiting |
| Genesis Research, LLC ( Site 0141) | Los Alamitos, California, United States | Active Not Recruiting |
| USC Norris Comprehensive Cancer Center ( Site 0123) | Los Angeles, California, United States | Recruiting |
| Genesis Healthcare-Torrance ( Site 0140) | Torrance, California, United States | Recruiting |
| Genesis Research LLC ( Site 0118) | Torrance, California, United States | Recruiting |
| Urology Associates ( Site 0144) | Littleton, Colorado, United States | Recruiting |
| Urological Research Network ( Site 0133) | Hialeah, Florida, United States | Recruiting |
| Associated Urological Specialists - Chicago Ridge ( Site 0139) | Chicago Ridge, Illinois, United States | Recruiting |
| Southern Urology, LLC ( Site 0145) | Lafayette, Louisiana, United States | Recruiting |
| University of Missouri Health Care ( Site 0126) | Columbia, Missouri, United States | Recruiting |
| NHO Revive Research Institute, LLC ( Site 0137) | Lincoln, Nebraska, United States | Recruiting |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0111) | New York, New York, United States | Recruiting |
+ 77 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06833073